CH678275A5 - - Google Patents
Download PDFInfo
- Publication number
- CH678275A5 CH678275A5 CH196589A CH196589A CH678275A5 CH 678275 A5 CH678275 A5 CH 678275A5 CH 196589 A CH196589 A CH 196589A CH 196589 A CH196589 A CH 196589A CH 678275 A5 CH678275 A5 CH 678275A5
- Authority
- CH
- Switzerland
- Prior art keywords
- treatment
- prophylaxis
- acridine
- intended
- diamino
- Prior art date
Links
- 238000011282 treatment Methods 0.000 claims abstract description 14
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 claims abstract description 13
- 208000005074 Retroviridae Infections Diseases 0.000 claims abstract description 8
- -1 heterocyclic nitrogenous compound Chemical class 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims abstract description 7
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 claims abstract description 6
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001441 aminoacridine Drugs 0.000 claims abstract description 6
- 208000030507 AIDS Diseases 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 229910017464 nitrogen compound Inorganic materials 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000008771 Lymphadenopathy Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 208000018555 lymphatic system disease Diseases 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 239000002831 pharmacologic agent Substances 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000798 anti-retroviral effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229960000286 proflavine Drugs 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 4
- 229940023020 acriflavine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000713880 Spleen focus-forming virus Species 0.000 description 1
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH196589A CH678275A5 (enrdf_load_html_response) | 1989-05-25 | 1989-05-25 | |
| PCT/CH1990/000132 WO1990014086A1 (fr) | 1989-05-25 | 1990-05-22 | Utilisation de derives de l'acridine dans le traitement d'infections retrovirales chez l'homme |
| AU56309/90A AU5630990A (en) | 1989-05-25 | 1990-05-22 | Utilisation of acridine derivatives in the treatment of retroviral infections in humans |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH196589A CH678275A5 (enrdf_load_html_response) | 1989-05-25 | 1989-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH678275A5 true CH678275A5 (enrdf_load_html_response) | 1991-08-30 |
Family
ID=4222755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH196589A CH678275A5 (enrdf_load_html_response) | 1989-05-25 | 1989-05-25 |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5630990A (enrdf_load_html_response) |
| CH (1) | CH678275A5 (enrdf_load_html_response) |
| WO (1) | WO1990014086A1 (enrdf_load_html_response) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2640508B1 (fr) * | 1988-12-19 | 1994-07-01 | Dietlin Francois | Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire |
| FR2711527A1 (fr) * | 1993-10-22 | 1995-05-05 | Richard Laboratoire M | Utilisation de l'acriflavine comme agent anti HIV. |
| FR2711526B1 (fr) * | 1993-10-22 | 1996-01-19 | Richard Laboratoire M | Utilisation de l'Acriflavine comme agent anti herpès et anti zona. |
| RU2103006C1 (ru) * | 1995-03-23 | 1998-01-27 | Олег Викторович Травкин | Иммуномодулирующее лекарственное средство |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3489837A (en) * | 1968-07-11 | 1970-01-13 | Leroy J Hyman | Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride |
| JPS61275228A (ja) * | 1985-03-14 | 1986-12-05 | バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド | 治療用タンパク組成物中のビ−ルスの光動的不活性化 |
-
1989
- 1989-05-25 CH CH196589A patent/CH678275A5/fr not_active IP Right Cessation
-
1990
- 1990-05-22 AU AU56309/90A patent/AU5630990A/en not_active Abandoned
- 1990-05-22 WO PCT/CH1990/000132 patent/WO1990014086A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990014086A1 (fr) | 1990-11-29 |
| AU5630990A (en) | 1990-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0278821B1 (fr) | Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis | |
| FR2656220A1 (fr) | Agents bloquants de l'effet ou de la formation du facteur edrf pour le traitement des chocs. | |
| FR2639226A1 (fr) | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs | |
| BE1003647A5 (fr) | Composition pharmaceutique de nicardipine pour administration parenterale. | |
| CA2107078A1 (fr) | Utilisation de la riboflavine dans le traitement de maladies liees aux virus vih, de l'herpes, de la retinite pigmentaire et du paludisme | |
| EP1745786A1 (fr) | Composés neuroprotecteurs et compositions pharmaceutiques les comprenant | |
| EP0437128B1 (fr) | Utilisation des dérivés des fluoroquinolones pour le traitement de la pneumonie à Pneumocystis carinii | |
| CH678275A5 (enrdf_load_html_response) | ||
| DE3785689T2 (de) | Verwendung von prostaglandin-biosynthese-hemmer. | |
| EP0185584B1 (fr) | Utilisation de l'hétéropolyanion (NaSb9W21086)18- pour fabriquer une composition pharmaceutique destinée à être utilisée dans le traitement du sida et des syndromes analogues | |
| NL8105635A (nl) | Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking. | |
| CH679982A5 (en) | Anti-retroviral compsn. contg. 2-methyl-9-hydroxy-ellipticine acetate - esp. for treatment or prevention of AIDS with greater activity than AZT | |
| FR2713487A1 (fr) | Solutions de type homéopathique contenant un acide nucléique utilisables notamment dans la prévention ou le traitement de maladies infectieuses ou de maladies impliquant le dysfonctionnement d'un gène. | |
| FR2515961A1 (fr) | Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie | |
| BE1004857A3 (fr) | Complexes de l'acide polyadenylique avec l'acide polyuridylique. | |
| EP0841909B1 (fr) | Utilisation de diamines alicycliques comme immunomodulateurs | |
| Mathov | The risks of monoamine oxidase inhibitors in the treatment of bronchial asthma | |
| FR2618676A1 (fr) | Compositions pharmaceutiques antivirales | |
| EP0470144B1 (fr) | D-acide aspartique beta-hydroxamate pour le traitement des infections virales et des tumeurs | |
| EP0004516A2 (fr) | Nouvelles compositions pharmaceutiques agissant sur la motricité gastro-intestinale | |
| FR2640508A1 (fr) | Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire | |
| KR940006591A (ko) | 비루스성 감염치료 방법 | |
| EP1001789B1 (fr) | Produit comprenant au moins un arn double brin en association avec au moins un derive du 6-benzyluracil pour une utilisation therapeutique simultanee, separee ou etalee dans le temps | |
| FR2715302A1 (fr) | Association pharmaceutique antivirale appropriée pour le traitement des infections par le virus HIV et du sida. | |
| WO1990011072A1 (fr) | Medicament pour le traitement des maladies infectieuses dues aux retrovirus ainsi que pour le traitement des tumeurs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |